Population pharmacokinetics of siltuximab: impact of disease state
Tóm tắt
To characterize the effects of disease type and clinical characteristics on the pharmacokinetics of siltuximab, an IL-6 inhibiting monoclonal antibody. Siltuximab pharmacokinetic data were combined from seven phase I/II clinical trials. A population pharmacokinetic model was developed to characterize changes in siltuximab disposition with disease type, albumin, liver and renal function, and patient demographics. A total of 7761 concentrations from 460 participants were used in the study. The data were well described by a two-compartment model. Castleman’s disease, healthy volunteer status, albumin, and ALT were independent predictors of clearance. Monte Carlo simulations of the final model for an 11 mg/kg dose resulted in a longer median half-life for healthy volunteers (24.5 days) as compared to Castleman’s disease (19.1 days) and other tumor types (22.2 days). Clearance varied 1.8-fold over the range of albumin values seen in the study (1.5–5.2 g/dL), while ALT resulted in minimal changes in clearance. Albumin and disease state are important factors for siltuximab disposition and will likely need to be considered for dosing in future therapeutic applications.
Tài liệu tham khảo
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636
Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish leukemia group. Blood 85(3):765–771
Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33(11):1794–1798
Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16(5):1652–1661. https://doi.org/10.1158/1078-0432.CCR-09-2581
Kumari N, Dwarakanath BS, Das A, Bhatt AN (2016) Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 37(9):11553–11572. https://doi.org/10.1007/s13277-016-5098-7
Tocilizumab package insert. https://www.gene.com/download/pdf/actemra_prescribing.pdf. Accessed Jan 26, 2019
El-Osta HE, Kurzrock R (2011) Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 16(4):497–511. https://doi.org/10.1634/theoncologist.2010-0212
Xie L, Li LY, Kurzrock R, van Rhee F, Qin X, Reddy M, Qi M, Davis HM, Zhou H, Puchalski TA (2012) Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-hodgkin’s lymphoma, multiple myeloma, or castleman’s disease. In: American Society of Hematology Annual Meeting, Atlanta, p 1365
A safety, efficacy and pharmacokinetic study of siltuximab (CNTO 328) in participants with solid tumors. https://clinicaltrials.gov/ct2/show/NCT00841191?term=siltuximab&draw=2&rank=14. Accessed Jan 12, 2019
A study evaluating the effects of siltuximab on the heart in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or indolent multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01219010?term=siltuximab&draw=2&rank=8. Accessed Jan 12, 2019
A study of siltuximab (anti- IL 6 monoclonal antibody) in patients with high-risk smoldering multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01484275?term=siltuximab&rank=7. Accessed Jan 12, 2019
A study to evaluate the efficacy and safety of CNTO328 plus best supportive care in multicentric castleman’s disease. https://clinicaltrials.gov/ct2/show/NCT01024036?term=siltuximab&draw=2&rank=15. Accessed Jan 12, 2019
A study to assess the safety and pharmacokinetics of a single intravenous administration of CNTO 328 derived from 2 different cell lines in healthy participants. https://clinicaltrials.gov/ct2/show/NCT02074800?term=NCT+02074800&rank=1. Accessed Jan 12, 2019
Pento JT (2017) Monoclonal antibodies for the treatment of cancer. Anticancer Res 37(11):5935–5939. https://doi.org/10.21873/anticanres.12040
Rossi JF, Lu ZY, Jourdan M, Klein B (2015) Interleukin-6 as a therapeutic target. Clin Cancer Res 21(6):1248–1257. https://doi.org/10.1158/1078-0432.CCR-14-2291
Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103(8):1154–1162. https://doi.org/10.1038/sj.bjc.6605872
Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol 6(9):576–588. https://doi.org/10.1002/psp4.12224
Ordas I, Mould DR, Feagan BG, Sandborn WJ (2012) Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91(4):635–646. https://doi.org/10.1038/clpt.2011.328
Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211–1228. https://doi.org/10.1007/s00228-009-0718-4
Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1):56–61